Why should you invest in Pfizer?

Why Pfizer is Catching Investors Eyes Right Now

If you have been looking at the pharmaceutical sector lately, you might have noticed that Pfizer is trading at a significant discount compared to its peers. From a purely quantitative standpoint, it currently stands out as one of the most affordable mega-cap stocks in the entire industry.

Right now, the stock is trading at roughly 9.3 times forward earnings. To put that into perspective, the broader industry average sits comfortably at over 18 times earnings. That kind of valuation gap naturally turns heads, especially for value-oriented portfolios.

Beyond the low valuation, income-focused investors are finding a lot to like. Pfizer’s dividend yield is holding steady at around 6.2%, making the stock a compelling option for those looking to generate reliable cash flow while waiting for long-term growth catalysts to play out.